Regeneron receives another CRL for its Eylea 8 mg | Optometry Times - Clinical News

Published on November 3, 2025
Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.
Continue reading on website
Other news

Neurotrophic keratitis in focus: Diagnosis, treatment, and practice pearls | Optometry Times - Clinical News

November 3, 2025
NK is more common than recognized; early diagnosis is paramount.

Kalaris Therapeutics Appoints Matthew Gall as Chief Financial Officer

November 4, 2025
PALO ALTO, Calif.—Kalaris Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for common retinal diseases, announced the expansion of its leadership team with the appointment of Matthew Gall, MBA, as its new chief financial officer (CFO). The appointment comes as Kalaris enrolls patients in its Phase 1b/2 study for treatment-naïve neovascul